tbuckley/cabot-search huggingface dataset:
Integrated Control of Proliferation and Differentiation of Mesenchymal Stem Cells
Authors: Michiko Filipak, David N. Estervig, Chin-Yuan Tzen, Parviz Minoo, Bryan J. Hoerl, Peter B. Maercklein, Michael A. Zschunke, Maryanne Edens, Robert E. Scott
Journal: Environmental Health Perspectives (1989)

The physiological control of cellular proliferation and differentiation is an integrated regulatory process. This conclusion is based upon observations using numerous in vivo and in vitro experimental systems of which murine BALB/c 3T3 T mesenchymal stem cells represent an excellent in vitro model. In these cells the coupling of growth arrest and differentiation occurs at a distinct biological state, and this predifferentiation arrest state is distinguishable by a variety of criteria from other restriction points, such as the growth factor deficiency arrest state and the nutrient deficiency arrest state. Most importantly, only cells at this predifferentiation arrest state acquire the potential to differentiate without undergoing DNA synthesis. From this state, differentiation can then occur as a two-step process. Cells first undergo nonterminal differentiation and, second, they terminally differentiate. Nonterminal differentiation is characterized by expression of a completely differentiated adipocyte phenotype with retention of proliferative potential. Thereafter, when nonterminally differentiated cells undergo the terminal event in differentiation, they irreversibly lose their proliferative potential. In this paper, data are reviewed which establish that the integrated control of proliferation and differentiation in 3T3 T mesenchymal stem cells is mediated both at the predifferentiation arrest state and at the state of nonterminal differentiation.
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
Authors: R. S. Herbst, Y. Sun, S. Korfee, P. Germonpré, N. Saijo, C. Zhou, J. Wang, P. Langmuir, S. J. Kennedy, B. E. Johnson
Journal: Journal of Clinical Oncology (2009)

CRA8003 Background: Vandetanib is a once-daily oral inhibitor of VEGFR, EGFR and RET signaling. Addition of vandetanib to docetaxel (doc) prolonged progression-free survival (PFS) in a randomized phase II study in patients (pts) with previously treated NSCLC (Heymach et al, JCO, 2007). Methods: The primary objective was to determine whether vandetanib 100 mg/day + doc 75 mg/m2 every 21 days (max 6 cycles) prolonged PFS vs placebo + doc. Secondary endpoints included overall survival, objective response rate (ORR), time to deterioration of symptoms (TDS) and safety. Efficacy and safety in females were assessed as a co-primary analysis population. Eligibility criteria included stage IIIB/IV NSCLC, PS 0–1, and previous first-line chemotherapy. Results: Between May 2006 and April 2008, 1,391 pts (mean age, 58 years; 30% female; 25% squamous; 10% brain mets) were randomized to vandetanib + doc (n=694) or placebo + doc (n=697). Baseline characteristics were similar in both arms. Median duration of follow-up was 12.8 months, with 87% patients progressed and 59% dead. Addition of vandetanib to doc showed a statistically significant improvement in PFS vs doc (hazard ratio [HR] 0.79, 97.58% CI 0.70–0.90; P<0.001), and a similar advantage in females (HR 0.79; P=0.024). Significant advantages for vandetanib + doc were also seen for ORR (17% vs 10%, P<0.001) and TDS (HR 0.78, P=0.002; FACT-L Lung Cancer Subscale). Overall survival showed a positive trend for vandetanib + doc that was not statistically significant (HR 0.91, 97.52% CI 0.78–1.07; P=0.196). The adverse event (AE) profile was consistent with that previously observed for vandetanib in NSCLC. Common AEs occurring more frequently in the vandetanib arm included diarrhea (42% vs 33%), rash (42% vs 24%) and neutropenia (32% vs 27%). Nausea (23% vs 32%), vomiting (16% vs 21%) and anemia (10% vs 15%) were less frequent in the vandetanib arm. The incidence of protocol-defined QTc prolongation was <2% in pts receiving vandetanib. Conclusions: The study met its primary objective of PFS prolongation with vandetanib + doc vs doc. Vandetanib is the first oral targeted therapy in phase III trials to show significant evidence of clinical benefit when added to standard chemotherapy in NSCLC. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca Oncology AstraZeneca Oncology, Genzyme Takeda AstraZeneca Oncology AstraZeneca Oncology, Chugai, Taiho, Takeda, Wyeth Genzyme
Medicolegal
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dr Mudd, the grandson, fights to clear name of famed ancestor
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The M5 Cell: A Color-Opponent Intrinsically Photosensitive Retinal Ganglion Cell
Authors: Maureen E. Stabio, Shai Sabbah, Lauren E. Quattrochi, Marissa C. Ilardi, P. Michelle Fogerson, Megan L. Leyrer, Min Tae Kim, Inkyu Kim, Matthew Schiel, Jordan M. Renna, Kevin L. Briggman, David M. Berson
Journal: Neuron (2018)
Queries and Minor Notes
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
JAMA Internal Medicine
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Lauren Fischer, John Mcfadden, Donald Smith, Karen Boyd, Rochelle Lodder, Diane Cannon, Connie Manno, Fred Marshall, Laura Copyreaders, Catherine Adamczyk, Stephanie Alden, Jan Beckmeyer, Mary Clavey, Paula Coerver-Connolly, Roya Glitman, Laura Khatiblou, Donna King, Caroline Thordsen, Wanda Assistant, Larry Bryant, Monica Mungle, Elaine Managers, Staff Gardner- Gullens, Fanny Brown, Paul Frank, Peter Kim, Rachell Lozano, Michaela Mark, Kathryn Muskovich, Gale Saulsberry, Michael Berkwits, Michelle Kurzynski, Eric Butkus, Will English, Christopher Hastings, Craig Mccaffrey, Reuben Rios, Ronna Henry, Joshua Bird, Karen Bucher, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Preeti Malani, Deanna Bellandi, Jim Periodical, Thomas Staff, Monica Smith, Jeffery Bonistalli Manager, Kathy Russell, Mirna Monal, Stacey Mchugh, Tim Melroy Classified, Thalia Moss, Mike Harvey, Susan Henning, Mark Thornbury, Tricia Castellano, Saskia Bolore, Gretchen Linder, Brian Mccartney, David Baum, Rebecca Haas, Christine Hearne, Irma Millie, Lara Marketing, Matt Herron, Elizabeth Solaro, Geoffrey Flick, Paul Gee Managers, Rick Bell, Lindsay Dawson, Michael Mcgraw, Sara Nagy, Romando Rossini, Stacy Staff, Millette Jackson-Bates, Karen Adams-Taylor, Karl Elvin, Sue Sherrill, Brian Shields Managers, David Antos, Chris Borden, Debbie Camp, Lydia Cruz, Scott Curl, Diane Darnell, Colleen Kelly, Chris Meyer, Jaye Mize, Annemarie Neff, J Neff, Sean O'donnell, Sean Ohlson, Phil O'leary, Susan Price, Denise Steinhauser, Production Services, Kim Boler, Rhonda Brown, Timothy Burke, Daniel Degroot, Jordynn Farrar, Euwanaha Joiner-Smith, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Dexter Golden, Erin Hinchcliff, Noemi Rivera, Geneine Van, Someren Composition, New Media, Gail Barrett, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Teri Hutchison, Mary Kuranda, Joshua Lampinen, Patricia Panek, La Son, Diggs Sledge, George Thomson Graphics, Joe Amft, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Daniel James, Judith Literskis, Teresa Omiotek, James Madara, Bernard Hengesbaugh, Jeffrey Tabas, San Francisco, Elsayed Soliman, Winston-Salem North, Carolina Gregory, M Marcus, Nora Goldschlager, California Cme, Rebecca Larson, Deborah Grady, Rosemary Gibson, Virginia Arlington, Mitchell Katz, Los Angeles, Patrick California, John Boscardin, John Neuhaus, Kenneth Covinsky, Joseph Ross, New Haven, Raman Khanna, Kathleen Mckibbin, Charlotte Dudley, Howard Bauchner, Rita Redberg, Shannon Brownlee, Tanner Caverly, Ann Arbor, Brandon Combs, Christopher Moriates, Neel Shah, Robert Steinbrook, Connecticut Web, Judyann Bigby, Ezekiel Emanuel, Mark Feinglos, Chi-Yuan Hsu, Kurt Kroenke, Grace Lin, Mary Mcdermott, C Noel, Bairey Merz, Samia California, Robert Phillips, Michael Pignone, Chapel Hill, North Carolina, Judith Prochaska, Kathryn Rexrode, Mary Tinetti, Nicolas Rodondi, Iona Heath
Journal: JAMA Internal Medicine (2014)
Heterosexually acquired HIV infection.
Journal: BMJ (1989)

increase has been only 1 6'%o.Let this be compared with the previous five vears (under Wilson/ Callaghan), when the average annual growth was 3-6%.With 1-6% growth £100 of expenditure in 1979 would have increased to £115.36 in 1988.With 3 6% annual growth its value would have increased to £137.48.This represents a shortfall in revenue for 1988 of 19-15%.I am sure that many of the problems of the district health authorities would be solved if their present income was increased by that amount.Even worse, however, is the accumulated loss of funding over the period.With the same £100 base the total loss in income over those nine years is £103.40,equivalent to a loss of 89-6% of the 1988 annual budget.This will inevitably become rapidly
Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.
Authors: Olivia Pagani, Meredith M. Regan, Barbara Walley, Gini F. Fleming, Marco Colleoni, Istvan Lang, Henry Leonidas Gomez, Carlo Tondini, Harold J. Burstein, Edith A. Perez, Eva Ciruelos, Vered Stearns, Herve R. Bonnefoi, Silvana Martino, Charles E. Geyer, Manuela Rabaglio-Poretti, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Prudence A. Francis
Journal: Journal of Clinical Oncology (2014)

LBA1 Background: Adjuvant endocrine therapy with AI vs T improves outcomes in postmenopausal HR+ BC. TEXT and SOFT were designed to test whether adjuvant AI improves outcomes in premenopausal women with HR+ BC treated with OFS (AI question) and to determine the value of OFS in women who remain premenopausal and are suitable for adjuvant T (OFS question). Methods: TEXT and SOFT, randomized phase 3 trials, enrolled 5,738 premenopausal women with HR+ early BC from Nov03 to Apr11 (2672 TEXT; 3066 SOFT). TEXT randomized women within 12wk of surgery to 5y E+OFS vs T+OFS; chemotherapy (CT) was optional and concurrent with OFS. SOFT randomized women to 5y E+OFS vs T+OFS vs T alone, either within 12wk of surgery if no CT planned, or within 8mo of completing (neo)adjuvant CT. OFS was by choice of 5y triptorelin, oophorectomy, or ovarian irradiation. The primary endpoint is disease-free survival (DFS: randomization until invasive local, regional, distant recurrence, or contralateral breast; 2nd malignancy; death). Due to low event rates, protocol amendments in 2011 changed the analysis plans to answer the AI question (E+OFS vs T+OFS) by joint analysis of TEXT and SOFT. By Q3’2013 with >5y median follow-up, 436 DFS events were projected, providing 84% power for HR=0.75 with E+OFS vs T+OFS (stratified logrank 2-sided α=0.05). Results: At 5.7y median follow-up, 514 (11%) DFS events were reported in the ITT population comparing E+OFS (n=2346) vs T+OFS (n=2344). Patients assigned E+OFS had significantly reduced DFS hazard (HR=0.72; 95% CI, 0.60-0.86; P=0.0002) vs T+OFS; 5y DFS was 91.1% vs 87.3%. Reductions were similar for secondary endpoints of BC-free interval (HR=0.66 (0.55-0.80) 5y BCFI 92.8% vs 88.8%) and distant recurrence-free interval (HR=0.78 (0.62-0.97)), though not overall survival (HR=1.14 (0.86-1.51)) at this early follow-up (194 (4%) deaths). Grade 3-4 targeted AEs were reported in 31% E+OFS vs 29% T+OFS patients. Conclusion: In premenopausal women with HR+ BC, adjuvant treatment with E+OFS significantly reduced the risk of recurrence compared to T+OFS. Clinical trial information: NCT00066703/NCT00066690.
REPORT OF THE SECRETARY OF THE SECTION ON SURGERY AND ANATOMY OF THE AMERICAN MEDICAL ASSOCIATION, AT THE MEETING IN CLEVELAND, JUNE, 1883.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Insulin Stimulates Human Skeletal Muscle Protein Synthesis via an Indirect Mechanism Involving Endothelial-Dependent Vasodilation and Mammalian Target of Rapamycin Complex 1 Signaling
Authors: Kyle L. Timmerman, Jessica L. Lee, Hans C. Dreyer, Shaheen Dhanani, Erin L. Glynn, Christopher S. Fry, Micah J. Drummond, Melinda Sheffield-Moore, Blake B. Rasmussen, Elena Volpi
Journal: Endocrine Reviews (2010)
Erosive Osteoarthritis.
Authors: J. B. Peter
Journal: Annals of Internal Medicine (1967)

s1 May 1967Erosive Osteoarthritis.J. B. Peter, M.D., Ph.D., Carl M. Pearson, M.D., F.A.C.P.J. B. Peter, M.D., Ph.D.Search for more papers by this author, Carl M. Pearson, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-66-5-1068_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptErosive osteoarthritis is an erosive, inflammatory, degenerative, osteophytic disease predominantly affecting the interphalangeal joints of the hands of middle-aged women. Data show that in the acute stage of this disease the synovium closely resembles that of rheumatoid arthritis from which erosive osteoarthritis is distinguished by clinical, laboratory, and roentgenographic features. In the chronic, burned-out, osteophytic stage the histopathology of synovium and cartilage resembles classical osteoarthritis. These and other observations make doubtful any specificity of the synovial histopathology in rheumatoid arthritis and reopen the question of possible synovial pathology in early osteoarthritis.Erosive osteoarthritis is frequently mistaken for rheumatoid arthritis because... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Los Angeles, California PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1967Volume 66, Issue 5Page: 1068-1069KeywordsCartilageClinical laboratoriesHistopathologyOsteoarthritisRheumatoid arthritisSpecificity Issue Published: 1 May 1967 PDF DownloadLoading ...
Giving visibility to accidentally swallowed toy
Authors: K. Glasbrenner
Journal: JAMA (1984)

Now, the invisible no longer has to be invisible when pediatricians treat children who swallow or inhale small plastic toys or their parts. Mattel Inc, Hawthorne, Calif, working with the Committee on Accident and Poison Prevention of the American Academy of Pediatrics (AAP), Evanston, Ill, has introduced a process that uses barium sulfate (BaSo<sub>4</sub>) in plastic toy production. This process makes small toys and small pieces of toys radiopaque. And, to enhance the plastic's visibility during the retrieval process, the industry-physician team now is preparing a list of colors to use or avoid in manufacturing such toys. According to Charles Williams, vice-president of quality, safety, and integrity at Mattel, this is the first year that all loose small parts used in Mattel toys are being made with BaSo<sub>4</sub>. He adds that such small parts are legal and are used only in toys intended and labeled for children older
TISSUE ACIDOSIS
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mycoplasma, amnionitis, and respiratory distress syndrome
Authors: P. A. Brunell
Journal: JAMA (1969)

<i>Mycoplasma hominis</i>type 1 was isolated from amniotic fluid obtained at cesarean section. Section was performed three days following rupture of the membranes in an effort to salvage an infant from a mother in whom puerperal sepsis had developed. Other organisms could not be recovered from the amniotic fluid specimen nor could bacteria be isolated from the mother's blood. Respiratory distress syndrome developed in the infant and he died. On pathological examination the lungs revealed evidence of interstitial pneumonia. No bacteria or hyaline membranes were seen.
Lincomycin: Thrombocytopenia?
Authors: MARTIN J. RAFF
Journal: Annals of Internal Medicine (1973)

Comments and Corrections1 May 1973Lincomycin: Thrombocytopenia?MARTIN J. RAFF, M.D.MARTIN J. RAFF, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-78-5-779_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Although thrombocytopenia has been implicated several times as a possible complication of therapy with lincomycin or 7-chlorlincomycin (1), a case has not yet been published in the literature.On 5 October 1972 a 56-year-old alcoholic black man was admitted to Louisville General Hospital with a diagnosis of aspiration pneumonia. Although no platelet count was obtained on admission, his peripheral smear showed 10 to 13 platelets per high-powered field. Intravenous therapy with lincomycin, 6 g/day, was begun on 6 October; when spontaneous epistaxis and petechiae appeared on 9 October, his platelet count was found to be 34 000/mm3....References1. : Personal communication Google Scholar2. LINDENBAUM J and HARGROVE R: Thrombocytopenia in alcoholics. Ann Intern Med 68:526-532, 1968 LinkGoogle Scholar3. POST R and DESFORGES J: Thrombocytopenia and alcoholism. Ann Intern Med 68:1230-1236, 1968 LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: MARTIN J. RAFF, M.D.Affiliations: University of Louisville School of Medicine Louisville, Kentucky PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1973Volume 78, Issue 5Page: 779-779KeywordsAlcoholicsPlateletsPneumonia ePublished: 1 December 2008 Issue Published: 1 May 1973 PDF downloadLoading ...